These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 21777819

  • 1. Natalizumab for multiple sclerosis: a complicated treatment.
    Keegan BM.
    Lancet Neurol; 2011 Aug; 10(8):677-8. PubMed ID: 21777819
    [No Abstract] [Full Text] [Related]

  • 2. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 3. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab.
    Hartung HP.
    Lancet Neurol; 2009 Jan; 8(1):28-31. PubMed ID: 19081511
    [No Abstract] [Full Text] [Related]

  • 4. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.
    Alvarez-Cermeño JC, Masjuan J, Villar LM.
    N Engl J Med; 2005 Oct 20; 353(16):1744-6; author reply 1744-6. PubMed ID: 16240475
    [No Abstract] [Full Text] [Related]

  • 5. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Oct 20; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 6. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 20; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab for relapsing multiple sclerosis.
    Jeffery DR.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
    [No Abstract] [Full Text] [Related]

  • 8. Natalizumab for relapsing multiple sclerosis.
    Tenser RB.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16738278
    [No Abstract] [Full Text] [Related]

  • 9. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab for relapsing multiple sclerosis.
    Meyer MA.
    N Engl J Med; 2006 Jun 01; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
    [No Abstract] [Full Text] [Related]

  • 11. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 12. [New drugs; natalizumab].
    van Bronswijk H, Dubois EA, van Gerven JM, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Mar 01; 152(9):499-500. PubMed ID: 18389881
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM.
    N Engl J Med; 2008 Jun 12; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract] [Full Text] [Related]

  • 14. Interruption of natalizumab therapy for multiple sclerosis: what are the risks?
    Naismith RT, Bourdette D.
    Neurology; 2011 May 31; 76(22):1854-5. PubMed ID: 21543735
    [No Abstract] [Full Text] [Related]

  • 15. Natalizumab and progressive multifocal leukoencephalopathy.
    Adelman B, Sandrock A, Panzara MA.
    N Engl J Med; 2005 Jul 28; 353(4):432-3. PubMed ID: 15947083
    [No Abstract] [Full Text] [Related]

  • 16. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 28; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract] [Full Text] [Related]

  • 17. Quantitative risk-benefit analysis of natalizumab.
    Steiner I.
    Neurology; 2009 May 19; 72(20):1791-2; author reply 1791-2. PubMed ID: 19451538
    [No Abstract] [Full Text] [Related]

  • 18. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 19. Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.
    Berger JR, Koralnik IJ.
    N Engl J Med; 2005 Jul 28; 353(4):414-6. PubMed ID: 15947082
    [No Abstract] [Full Text] [Related]

  • 20. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
    Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.
    Lancet Neurol; 2011 Aug 28; 10(8):745-58. PubMed ID: 21777829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.